Does the Kinin System Mediate in Cardiovascular Abnormalities? An Overview

Journal of Clinical Pharmacology

Volumn 43, Issue 11, 2003, Pages 1187-1195

  Sharma, Jagdish N ^a  

^a KUWAIT UNIVERSITY   (Kuwait)

Author keywords

Angiotensin converting enzyme inhibitors; Cardiac diseases; Cardioprotection; Hypertension; Kallikrein kinin system

Indexed keywords

B 5630; B 6572; B 9430; BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; BRADYKININ; BRADYKININ ANTAGONIST; BRADYKININ B1 RECEPTOR AGONIST; BRADYKININ B1 RECEPTOR ANTAGONIST; BRADYKININ B2 RECEPTOR AGONIST; BRADYKININ RECEPTOR; BRADYKININ, DES ARG(9); BRADYKININ, DES-ARG(9)-; BRADYKININ[1 [3 (2 NAPHTHYL)ALANINE] 5,8 [3 (2 THIENYL)PHENYLALANINE] 7 DEXTRO PHENYLALANINE]; BRADYKININ[5,8 [3 (2 THIENYL)ALANINE] 7 DEXTRO PHENYLALANINE]; BRADYKININ[8 LEUCINE 9 DEARGININE]; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; DELTIBANT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRUG DERIVATIVE; KALLIKREIN; KININ; NIFEDIPINE; NITRIC OXIDE SYNTHASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MALFORMATION; DIABETES MELLITUS; DRUG EFFECT; DRUG SYNTHESIS; ENZYME RELEASE; GENE DELIVERY SYSTEM; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; HYPERTENSION; KALLIKREIN KININ SYSTEM; KIDNEY DISEASE; METABOLISM; NONHUMAN; PATHOPHYSIOLOGY; PHYSIOLOGY; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMALS; BRADYKININ; CARDIOVASCULAR ABNORMALITIES; HUMANS; KININS; RECEPTORS, BRADYKININ;

EID: 0142103703     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270003258171     Document Type: Review

References (108)

1. Nolly HL, Brotis J: Kinin-forming enzyme in rat cardiac tissue. Am J Physiol 1981;265:H1209-H1214.
2. Sharma JN, Uma K: Cardiac kallikrein in hypertensive and diabetic rats with and without diabetes. Immunopharmacology 1996;33:341-343.
3. Sharma JN, Uma K, Yusof APM: Left ventricular hypertrophy and its relation to the cardiac kinin-forming system in hypertensive and diabetic rats. Int J Cardiol 1998;63:229-235.
4. Sharma IN, Uma K, Yusof APM: Altered cardiac tissue and plasma kininogen levels in hypertensive and diabetic rats. Immunopharmacology 1999;34:129-132.
5. Oza NB, Goud HD: Kiniogeses of the aortic wall in spontaneously hypertensive rats. J Cardiovasc Pharmacol 1992;20(Suppl. 9):1-3.
6. Nolly HL, Carretero OA, Sclicli AJ: Kallikrein release by vascular tissue. Am J Physiol 1993;265:H1209-H1214.
7. Vegh A, Szekeres L, Parratt RJ: Local intracoronary infusions of bradykinin profoundly reduce the severity of ischaemia-induced arrhythmia in anaesthetized dogs. Br J Pharmacol 1991;104:294-295.
8. Linz W, Wiemer G, Scholkens BA: Bradykinin prevents left ventricular hypertrophy in rats. J Hypertens 1993;11(Suppl. 5):S96-S97.
9. Vegh A, Rapp JG, Parratt JR: Attenuation of the antiarrhythmic effects of ischaemia preconditioning by blocked off bradykinin B2 receptors. Br J Pharmacol 1994;107:1167-1172.
10. Walls TM, Sheehy R, Hartman JC: Role of bradykinin in myocardial preconditioning. J Pharmacol Exp Ther 1994;270:681-689.
11. Linz W, Wiemer G, Scholkens BA: Contribution of bradykinin to the cardiovascular effects of ramipril. J Cardiovasc Pharmacol YEAR;22(Suppl. 9):S1-S8.
12. Sharma JN: Kinin-forming system in the genesis of hypertension. Agents Actions 1984;14:200-205.
13. Sharma JN: Interrelationship between the kallikrein-kinin system and hypertension: a review. Gen Pharmacol 1988;19:177-187.
14. Sharma JN: Contribution of kinin system to the antihypertensive action of angiotensin converting enzyme inhibitors. Adv Exp Med Biol 1989;247A:197-205.
15. Sharma JN, Uma K, Noor AR, Rahman AR: Blood pressure regulation by the kallikrein-kinin system. Gen Pharmacol 1996;27:55-63.
16. Sharma JN: Does kinin mediate the hypotensive action of angiotensin converting enzyme (ACE) inhibitors. Gen Pharmacol 1990;21:451-457.
17. Sharma JN: Involvement of the kinin-forming system in physiopathology of rheumatoid inflammation. Agents Actions 1992;38(3):343-361.
18. Nagayasa T, Nagasawa S: Studies of human kininogen: isolation, characterization, and cleavage by plasma kallikrein of high molecular weight (HMW) kininogen. J Biochem 1979;85:249-258.
19. Muller-Esterl W, Iwanaga S, Nakanishi S: Kininogens revisited. Trend Pharmacol Sci 1986;11:336-339.
20. Greenbaum LM: T-kinin and T-kininogen, children of technology. Biochem Pharmacol 1986;33:2943-2944.
21. Okamoto H, Greenbaum LM: Pharmacological properties of T-kinin. Biochem Pharmacol 1983;32:2637-2638.
22. Nustad K, Vaaje K, Pierce JV: Synthesis of kallikrein by rat kidney slices. Br J Pharmacol 1975;53:229-234.
23. Sharma JN, Zeitlin IJ, Deodhar SD, Buchanan WW: Detection of tissue kallikrein-like activity in inflamed synovial tissue. Archives Internationales de Pharmacodynamies et de Therapie 1983;262:279-286.
24. Bhoola KD, Figueroa CD, Worthy K: Bioregulation of kinin, kallikrein, kininogen and kininases. Pharmacol Rev 1992;44:1-80.
25. Takada Y, Skidgel RA, Erdos EG: Purification of human urinary prokallikrein: identification of the site of activation by the metalloproteinase thermolysin. Biochem J. 1985;232:851-856.
26. Weiss AS, Gallin JL, Kaplan AP: Fletcher factor deficiency: a diminished rate of Hageman factor activation caused by absence of prekallikrein with abnormalities of coagulation, fibrinolysis, chemotactic activity and kinin generation. J Clin Invest 1974;53:622-633.
27. Cochrane CG, Revak SD, Wuepper D: Activation of Hageman factor in solid and fluid phase: a critical role of kallikrein. J Exp Med 1973;138:1564-1583.
28. Griffin JH, Cochrane CG: Mechanism for the involvement of high molecular weight kininogen in surface-dependent reactions of Hageman factor. Proc Natl Acad Sci USA 1976;73:2554-2558.
29. Manddle R, Colman RW, Kaplan A: Identification of prekallikrein and HMW-kininogen as a complex in human plasma. Proc Natl Acad Sci USA 1976;73:4176-4183.
30. Thampson RE, Mandle R, Kaplan AP: Association of factor XI and high molecular weight kininogen in human plasma. J Clin Invest 1977;60:1376-1380.
31. Silverberg M, Diehl S: The autoactivation of factor XII (Hageman factor) induced by low-heparin and dextran sulfate. Biochem J 1987;248:715-720.
32. Woolly-Miller C, Chao J, Chao L: Restriction fragment length polymorphisms mapped in spontaneously hypertensive rats using kallikrein probs. J Hypertens 1989;7:865-871.
33. Pravenc M, Ken V, Kunes J, Sclicli G, Carretero OA, Simonet L, et al. Cosegregation of blood pressure with a kallikrein gene family polymorphism. Hypertension 1991;17:242-246.
34. Erdos EG: Some old and some new ideas on kinin metabolism. J Cardiovasc Pharmacol 1990;15(Suppl. 6):S20-S24.
35. Marceau F, Hess JF, Bachvarov DR: The B1 receptors for kinin. Pharmacol Rev 1998;50:357-386.
36. Regoli D: Neurohumoral regulation of precapillary vessels: the kallikrein-kinin system. J Cardiovasc Pharmacol 1984;6(Suppl. 3):S401-S412.
37. D'Orleans-Juste P, de Nussi G, Vane JR: Kinins act on B1 or B2 receptors to release conjointly endothelium-derived relaxing factor and prostacyclin from bovine aortic endothelial cells. Br J Pharmacol 1989;96:920-926.
38. Tiffany CW, Burch M: Bradykinin stimulates tumor necrosis factor and interleukin-1 release from macrophages. FEBS Lett 1989;247:189-192.
39. Whalley ET, Clegg S, Stewart JM, Vavrek RJ: The effect of kinin agonists and antagonists on the pain response of human blister base. Naunyn-Schmiedeberg Arch Pharmacol 1987;336:652-655.
40. Sharma JN, Yusof APM: Pro-inflammatory properties of the kallikrein-kinin system: potential for new drug therapy. Inflammopharmacology 1998;6:289-296.
41. Sharma JN, Yusof APM, Wirth KJ: The kinin antagonist Hoe 140 reduces acute paw oedema in rats caused by carrageenan, bradykinin and kaolin. Inflammopharmacology 1988;6:9-17.
42. Jin LS, Seeds E, Page C, Schachter M: Inhibition of bradykinin-induced bronchoconstriction in guinea-pig by a synthetic B2 receptor antagonist. Br J Pharmacol 1989;97:598-602.
43. Sharma JN, Stewart JM, Mohsin SSJ, Katori M, Vavrek R: Influence of a kinin antagonist on acute hypotensive responses induced by bradykinin and captopril in spontaneously hypertensive rats. Agents Actions 1992;38(3):258-269.
44. Abbas SA, Sharma JN, Yusof APM: Effect of bradykinin and its antagonist on survival time after coronary artery occlusion in rats, Gen Pharmacol 1999;33:243-247.
45. Abbas SA, Sharma JN, Yusof APM: The effect of bradykinin and its antagonist on survival time after coronary artery occlusion in hypertensive rats. Immunopharmacology 1999;44:93-98.
46. Barabe J, Droulin JN, Regoli D, Park WK: Receptors for bradykinin in intestine and uterine smooth muscle. Can J Physiol Pharmacol 1977;96:920-926.
47. Farmer SG, Burch RM, Meeker SA, Wilkins DE: Evidence for a pulmonary B3 bradykinin receptor. Mol Pharmacol 1989;36:1-8.
48. Saha JK, Sengupta JN, Goyal RK: Effect of bradykinin on opossum longitudinal smooth muscle: evidence for novel bradykinin receptors. J Pharmacol Exp Ther 1990;252:1012-1020.
49. Saha JK, Sengupta JN, Goyal RK: Effect of bradykinin and bradykinin analogs on the opossum lower esophageal sphincter: characterization of an inhibitory bradykinin receptor. J Pharmacol Exp Ther 1991;259:265-273.
50. Regoli D, Barabe J: Pharmacology of bradykinin and related kinins. Pharmacol Rev 1980;32:1-46.
51. Varvrek R, Stewart JM: Competitive antagonists of bradykinin. Peptides 1985;6:161-164.
52. Wirth KJ, Hock FJ, Albus U, Linz W, Alphermann HG, Anagnostopoulos H, et al: Hoe 140 a new potent and long acting bradykinin antagonist: in vitro studies. Br J Pharmacol 1991;102:774-777.
53. Cheronis JC, Whally ET, Nguyen KT: A new class of bradykinin antagonist: synthesis and in vitro activity of bissuccinimidoalkane peptide dimmers. J Med Chem 1992;35:1563-1572.
54. Hanson L, McCullough RG, Selig WM: In vivo pharmacological profile of novel, potent, stable BK antagonist at B1 and B2 receptors. Immunopharmacology 1996;33:191-193.
55. Burgess GM, Perkins MN, Rang PR, Cambell EA, Brown MC, McIntyre P, et al: Bradyzide, a potent non-peptide B2 bradykinin receptor antagonist with long-lasting oral activity in animal models of inflammatory hyperalgesia. Br J Pharmacol 2000;129:77-86.
56. Farmer SG, Burch RM: Biochemical and molecular pharmacology of kinin receptors. Annu Rev Pharmacol Toxicol 1992;32:511-536.
57. Burch RM: Kinin signal transduction: role of phosphoinositides and eicosanoids. J Cardiovasc Pharmacol 1990;15(Suppl. 6):S44-S46.
58. Sbarma JN, Zeitlin IJ: Indomethacin in low concentrations potentiates the action of some spasmogens on the isolated oestrous rat uterus. J Pharm Pharmacol 1977;29:316-317.
59. Akbar A, Sharma JN, Yusof APM, Gan EK: Potentiation of bradykinin-induced responses in the intact and denuded epithelium of guinea pig tracheal preparations. Tissue React 1998;20:95-100.
60. Ransom RW, Young GS, Schneck K, Goodman CB: Characterization of solubilized bradykinin B2 receptors from smooth muscle and mucosa of guinea-pig ileum. Biochem Pharmacol 1992;43:1823-1827.
61. Schini VB, Boulanger C, Regoli D, Vanhoutte PM: Bradykinin stimulates the production of cyclic GMP via activation of B2 receptors in cultured porcine aortic endothelial cells. J Pharmacol Exp Ther 1990;252:581-585.
62. Adetuyibi A, Mills IH: Relationship between urinary kallikrein and renal function, hypertension, and excretion of sodium and water in man. Lancet 1972;2:203-207.
63. De Freitas FM, Farraco EZ, de Azevedo DF: General circulatory alterations induced by intravenous infusion of synthetic bradykinin in man. Circulation 1964;29:66-70.
64. Webster ME, Gilmore JP: Influence of kallidin-10 on renal function. Am J Physiol 1964;206:714-718.
65. McGiff JC, Itskovitz HD, Terrango NA: The action of bradykinin and eledoicin in the canine isolated kidney: relationship to prostaglandins. Clin Sci Mol Med 1975;49:125-131.
66. Margolius HS, Geller R, Pisano JJ, Sjoerdsma A: Altered urinary kallikrein excretion in human hypertension. Lancet 1971;2:1063-1065.
67. Margolius HS, Geller R, deJong W, Pisano JJ, Sjoerdsma A: Altered urinary kallikrein excretion in rats with hypertension. Circ Res 1972;30:358-362.
68. Sharma JN, Zeitlin IJ: Altered plasma kininogen in clinical hypertension. Lancet 1981;1:125-126.
69. Sharma JN: Kinin system and prostaglandins in the intestine. Pharmacol Toxicol 1988;63:310-316.
70. Almeida FA, Stella RCR, Voos A, Ajzen H, Riberio AB: Malignant hypertension: a syndrome associated with low plasma kininogen and kinin potentiating factor. Hypertension 1981;3:46-50.
71. James FW, Donaldson VH: Decrease exercise tolerance and hypertension in serve hereditary deficiency of plasma kininogen. Lancet 1981;1:889.
72. Mohsin SSJ, Majima M, Katori M, Sharma JN: Important suppressive roles of the kallikrein-kinin system during the developmental stage of hypertension in spontaneously hypertensive rats. Asia Pac J Pharmacol 1992;7:73-82.
73. Katori M, Majima M: Role of the renal kallikrein-kinin system in the development of hypertension. Immunopharmacology 1997;36:237-242.
74. Wang C, Chao L, Chao J: Human tissue kallikrein induces hypotension in transgenic mice. Hypertension 1994;23:236-243.
75. Sharma JN, Amrah SS, Noor AR: Suppression of hypotensive responses of captopril and enalapril by kallikrein inhibitors aprotinin in spontaneously hypertensive rats. Pharmacology 1995;50:363-369.
76. Chao J, Chao L: Kallikrein gene therapy in hypertension, cardiovascular and renal diseases. Gene Ther Mol Biol 1998;1:301-308.
77. Silberbauer K, Stanek B, Temple H: Acute hypotensive effect of captopril in man modified by prostaglandin synthesis inhibition. Br J Clin Pharmacol 1982;14:87S-93S.
78. Antonaccio M: Angiotensin converting enzyme (ACE) inhibitors. Annu Rev Pharmacol Toxicol 1982;22:57-87.
79. Sharma JN, Ferandez PG, Kim BK, Triggle CR: Systolic blood pressure responses to enalapril maleate (MK 421), an angiotensin converting enzyme inhibitor and hydrochlorothiazide in conscious Dahl salt-sensitive (S) and salt-resistant (R) rats. Can J Physiol Pharmacol 1984;62:241-243.
80. Edery H, Rosenthal T, Amitzur G, Rubinstein A, Stem N: The influence of SQ 20881 on the blood kinin system of renal hypertensive patients. Drug Exp Clin Res 1981;7:749-756.
81. Smith C, Campbell S, Albano J: Urinary kallikrein excretion in normotensive and hypertensive pregnancies: 8 years later. Immunopharmacology 1990;44:177-182.
82. Sharma JN: Therapeutic prospects of bradykinin antagonists. Gen Pharmacol 1993;24:267-274.
83. Branuwald E: Cardiovascular medicine at turn of the millennium: triumphs, concern and opportunities. N Engl J Med 1997;337:1360-1369.
84. Lochner W, Parratt JR: A comparison of the effects of locally and systemically administered kinin on coronary blood flow and myocardial metabolism. Br J Pharmacol Chemother 1966;26:17-26.
85. Linz W, Wiemer G, Gohlke P: Contribution of kinin to the cardiovascular action of converting-enzyme inhibitors. Pharmacol Rev 1995;47:25-50.
86. Zhu P, Zugga CE, Simper D, Hornstein P, Allegrini PR, Buser PT: Bradykinin improves postischaemic recovery in the rat heart: role of high energy phosphates, nitric oxide and prostacyclin. Cardiovasc Res 1995;29:658-663.
87. Madeddu P, Milia AF, Salis MB, Gaspa L, Gross W, Lippoldt A, et al: Renovascular hypertension in bradykinin B2-receptor knockout mice. Hypertension 1998;23:305-509.
88. Kichuck MR, Seyedi N, Zhang X, Marboe CC, Michler RE, Addonzio LJ, et al: Regulation of nitric acid production in human coronary microvessels and the contribution of local kinin formation. Circulation 1996;94:44-51.
89. Whalley ET, Soomon JA, Modafferi DM: CP-0127, a novel potent bradykinin antagonist increases survival in rat and rabbit model of endotoxin shock. Agents Actions 1992;38(Suppl.):431-420.
90. Koide A, Zeitlin IJ, Parratt JR: Kinin formation in ischaemic heart and aorta of anaesthetized rats. J Physiol (Lond) 1993;467:125P.
91. Scholkens BA: Kinins in the cardiovascular system. Immunopharmacology 1996;33:209-217.
92. Rubin LE, Levi R: Protective role of bradykinin in cardiac anaphylaxis. Circ Res 1995;79:434-440.
93. Yoshida H, Zhang JJ, Chao L, Chao J: Kallikrein gene delivery attenuates myocardial infarction and apoptosis after myocardial ischaemia and perfusion. Hypertension 2000;35:25-31.
94. Sharma JN, Abbas SA, Yusof APM, Shah RJ: Evaluation of tissue kallikrein activity on survival time after acute coronary artery ligation in hypertensive rats. Int Immunopharmacology 2003;3:329-234.
95. Sharma JN, Kesavarao U: Effect of captopril on urinary kallikrein, blood pressure and myocardial hypertrophy in diabetic spontaneously hypertensive rats. Pharmacology 2002;64:196-200.
96. Dela CR, Suffredini A, Page JD, Pixley RA, Kaufman N, Parrillo JE, et al: Activation of kallikrein-kinin system after endotoxin administration to normal human volunteers. Blood 1993;81:3313-3317.
97. Nies AS, Forsyth RP, Williams HE, Melmon KL: Contribution of kinins to endotoxin volunteers. Blood 1993;81:3313-3317.
98. , Nies AS, Forsyth RP, Williams HE, Melomon KL: Contribution of kinins to endotoxin shock in unanesthetized Rhesus monkeys. Circ Res 1968;22:155-164.
99. Kontos MA, Dagee JH, Shapiro W: General and circulatory effects of synthetic bradykinin in man. Circ Res 1964;14:352.
100. Wilson DD, DeGaravilla L, Kihn W, Togo J, Bruch RM, Steranka LR: D-Arg-{Hyp3-D-Phe7}-bradykinin, a bradykinin antagonist reduces mortality in a rats model of endotoxin shock. Circ Shock 1989;27:93-101.
101. Feletou M, Lonchmpt M, Robineau P, Iamonneau I, Thurieau C, Fauchere JL, et al: Effects of bradykinin B2 receptor antagonist S 16118 p-guanidobenzoyl-[hyp3, Thi5, D-Tic7, Oic8] bradykinin in different in vivo animal models of inflammation. J Pharmacol Exp Ther 1995;237:1078-1085.
102. Cheng CP, Onishi K, Ohte N, Suzuki, Little WC: Functional effects of endogenous bradykinin in congestive heart failure. Am J Coll Cardiol 1998;31:1679-1686.
103. Fein AM, Bernard GR, Criner GJ: Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127). JAMA 1997;277:482-487.
104. McLean PG, Perretti M, Ahluwalia A: Inducible expression of the kinin B1 receptor in the endotoxemic heart: mechanisms of de-Arg9 bradykinin induced coronary vasodilation. Br J Pharmacol 1999;128:275-282.
105. Steranka LR, Farmer SG, Burch RM: Antagonists of B2 bradykinin receptors. FASEB J 1989;3:2019-2025.
106. Regoli D, Rhaleb NE, Tousignant C, Rouissi N, Nantel F, Jukie D, et al: New highly potent bradykinin B2 receptor antagonists. Agents Actions 1991;34138-34141.
107. Stewart JM, Vavrek RJ: Bradykinin competitive antagonists. Adv Exp Med Biol 1986;198:537-542.
108. Lembeck F, Griesbacher T: Functional analysis of kinin antagonists. J Cardiovasc Pharmacol 1990;15(Suppl. 6):S75-S77.